Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524703 | NSE Symbol : | ISIN : INE751D01014 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
04-Feb-2025	13-Feb-2025	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve 1.Approval of Standalone Unaudited Financial Results for Q ended 31st December 2024 2. any other matter with permission of chairman Appointment of the Internal Auditor for the FY 2025-26 (As Per BSE Announcement Dated on 13/02/2025)
04-Nov-2024	14-Nov-2024	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve approval of standalone and consolidated unaudited financials results for quarter and half year ended 30.09.2024 outcome of the Board Meeting dated 14th November 2024 (As Per BSE Announcement Dated on 14.11.2024) Corrigendum to the Outcome of the Board Meeting held on 14th November 2024 (As Per BSE Announcement Dated on 15.11.2024)
03-Aug-2024	12-Aug-2024	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve 1. To Approve Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter ended 30th June 2024. 2. To Consider and appoint Shri. Vijay Kottapalli (DIN: 10245156) as Additional Director (Non Executive Independent Director) of the Company. 3. To consider/recommend Dividend for the Financial Year 2023-24. Outcome of the Board Meeting dated 12th August 2024 (As Per BSE Announcement Dated on 12.08.2024)
31-May-2024	05-Jun-2024	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/06/2024 inter alia to consider and approve 1. Approval of Standalone and Consolidated Financials for the Q and Year ended 31.03.2024 2.Any other matter with permission of the Chairman Audited Results (Revised) (As Per Bulletin Dated on: 30/05/2024 Outcome of the Board Meeting Audited Financial Results for the year ended 31.03.2024 (As Per BSE Announcement Dated on: 05/06/2024)
20-May-2024	30-May-2024	Change in Auditors	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve 1. To Approve Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Year ended 31st March 2024 2. To Consider and Reappoint CMA Shekhar Joshi & Co Cost Accountants (Registration No. 100448) as Cost Auditor of the Company for the Financial Year 2024-25. 3. Any other matter with the permission of Chairman. Outcome of the Board Meeting dated 30th May 2024 (As Per BSE Announcement Dated on: 30/05/2024) Audited Results (Revised) Outcome of the Board Meeting dated 30th May 2024 (As Per Bulletin Dated on: 30/05/2024)
20-Mar-2024	30-Mar-2024	Change in Other Executives	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/03/2024 inter alia to consider and approve 1. To Consider and Appoint Chief Financial Officer of the Company. 2. Any other matter with the permission of Chairman. Outcome of the Board Meeting dated 30th March 2024 (As Per BSE Announcement dated on 30.03.2024)
05-Feb-2024	14-Feb-2024	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve 1. To Approve Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter 31st December 2023. 2. Any other matter with the permission of Chairman. unaudited financials results for Q ended 31st December 2023 Outcome of the Board Meeting dated 14.02.2024 (As Per BSE Announcement Dated on: 14/02/2024)
03-Nov-2023	13-Nov-2023	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2023 inter alia to consider and approve Approval of Unaudited Financials for the Q and Half year ended 30th Sept 2023 Outcome of the Board Meeting for half year ended 30th September 2023 Standalone and consolidated financials for the quarter and half year ended 30th September 2023 (As Per BSE Announcement Dated on 13/11/2023)
04-Aug-2023	14-Aug-2023	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve 1. To Approve Unaudited standalone and consolidated Financial Results of the Company for the Quarter ended 30th June 2023. 2. To consider/recommend Dividend for the Financial Year 2022-23. 3. Any other matter with the permission of Chairman. Quarterly Results & Final Dividend (As per BSE Bulletin dated on 04/08/2023) Board approved dividend Board of Director at their Meeting Held on 14th August 2023 has recommended Dividend at the rate of Rs 0.75 paisee per Equity Shares (i.e 7.5 percent on paid up share Capital of the Company for the Financial Year ended 31st March 2023 ,subject to approval of the final dividend by the Shareholders at the 37th Annual General Meeting. We further would like to inform you that Rest all the items mentioned in the Outcome of the Meeting remains unchanged. You are requested to kindly take the same on record. change in directorate Standalone and consolidated financials for the q ended 30th June 2023 Disclosure about Regulation 30 of SEBI (LODR) (As Per BSE Announcement Dated on 14.08.2023) communication to shareholders regarding Tax Deduction at Source (TDS) on dividend income (As Per BSE Announcement Dated on 13/09/2023)
20-May-2023	30-May-2023	Accounts	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve 1. To Approve Audited Financial Results of the Company for the Quarter and Year ended 31st March 2023 2. To Consider and Reappoint CMA Shekhar Joshi & Co Cost Accountants (Registration No. 100448) as Cost Auditor of the Company for the Financial Year 2023-24. 3. Any other matter with the permission of Chairman. Outcome of the Board Meeting dated 30th May 2023 (As Per BSE Announcement dated on 30.05.2023)
03-Feb-2023	14-Feb-2023	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Unaudited Financial Results for Q ended 31st December 2022 1. Considered, Approved and took on record Unaudited Financial Results for the Quarter 31st December 2022. 2. Took note of Statement of Utilizations and Deviations as per Regulation 32 of SEBI (LODR) Regulation 2015 for the Quarter ended 31st December 2022.. 3. Reappointed M/s Akhil Pai & Co, and M/s Uday & Uday Associates Chartered Accountant as the Internal Auditor for the Goa Factory and Mumbai office vice versa for the financial year 2023-24. 4. Amended Policy on Related Party Transactions. Unaudited standalone and consolidated financial results for q ended 31.12.2022 (As Per BSE Announcement Dated on 14.02.2023)
01-Nov-2022	14-Nov-2022	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve 1. Declaration of Unaudited Financial Results for Q ended 30.09.2022 2.Any other matter with permission of Chairman Outcome of the Board Meeting held on 14th November 2022 (As Per BSE Announcement Dated on 14.11.2022)
30-Jul-2022	12-Aug-2022	Quarterly Results	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2022 inter alia to consider and approve 1. To Approve Unaudited Financial Results of the Company for the Quarter 30th June 2022. 2. To consider/recommend Dividend for the Financial Year 2021-22. 3. Any other matter with the permission of Chairman. Compliance of Reg 29(1)(e) of SEBI (LODR) Regulation 2015-Board to consider Dividend (As Per BSE Announcement Dated on 30/07/2022) Outcome of the Board Meeting Unaudited Financials for Q ended 30.06.2022 (As Per BSE Announcement Dated on 12.08.2022) Board has recommended Dividend at the rate of Rs 0.75 paisee per Equity Shares (i.e 7.5 percent on paid up share Capital of the Company for the Financial Year ended 31st March 2022,subject to approval of the final dividend by the Shareholders at the 37th Annual General Meeting, which was inadvertently due to clerical mistake was mentioned as 0.75percent instead of 7.5 percent to paid up capital of the Company. Revised Outcome of the Board Meeting with Scrip Code 524703 in respect of the Dividend (As Per BSE Bulletin Dated on 29.08.2022)
02-Jul-2022	07-Jul-2022	Change in Auditors	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/07/2022 inter alia to consider and approve 1. To Consider and Reappoint CMA Shekhar Joshi & Co Cost Accountants (Registration No. 100448) as Cost Auditor of the Company for the Financial Year 2022-23. 2. To Consider/Approve/Discuss on 03RD and Final Tranche conversion of 850326 nos of Equity Warrants Conversion into Equity Shares. 3. Any other matter. Outcome of the Board Meeting dated 07th July 2022 (As per BSE Announcement Dated on 07/07/2022)
15-May-2022	30-May-2022	Accounts	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve 1.Approval of audited financial results for quarter and year ended 31st march 2022 2.any other item with permission of Chairman Outcome of the Board Meeting dated 30th May 2022 (As Per BSE Announcement Dated on 30/05/2022)

1 2

LOGIN HERE

Sandu Pharmaceuticals Ltd

Board Meeting